Targeting mutant BRAF in relapsed or refractory hairy-cell leukemia Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Indoles
  • Leukemia, Hairy Cell
  • Proto-Oncogene Proteins B-raf
  • Sulfonamides

abstract

  • A short oral course of vemurafenib was highly effective in patients with relapsed or refractory hairy-cell leukemia. (Funded by the Associazione Italiana per la Ricerca sul Cancro and others; EudraCT number, 2011-005487-13; ClinicalTrials.gov number NCT01711632.).

authors

publication date

  • January 2015

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4811324

Digital Object Identifier (DOI)

  • 10.1056/NEJMoa1506583

PubMed ID

  • 26352686

Additional Document Info

start page

  • 1733

end page

  • 47

volume

  • 373

number

  • 18